Ascelia Pharma AB (publ) (ACE) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.137x

Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has a cash flow conversion efficiency ratio of -0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.66 Million ≈ $-1.69 Million USD) by net assets (Skr114.40 Million ≈ $12.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ascelia Pharma AB (publ) (ACE) balance sheet quality index to measure how much of total assets are equity-financed.

Ascelia Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Ascelia Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Ascelia Pharma AB (publ) long-term investment intensity to see how much of total assets are deployed in long-term investments.

Ascelia Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
U-BX Technology Ltd. Ordinary Shares NASDAQ:UBXG	-0.017x
Lodestar Minerals Ltd AU:LSR	3.339x
Zwahlen et Mayr SA SW:ZWM	-0.106x
Iex Group NV AS:IEX	0.216x
Maisons du Monde SAS PA:MDM	-0.014x
Culpeo Minerals Ltd AU:CPO	-0.105x
Raj Oil Mills Limited NSE:ROML	1.915x
Ictsi Jasa Prima Tbk JK:KARW	0.015x

Annual Cash Flow Conversion Efficiency for Ascelia Pharma AB (publ) (2017–2024)

The table below shows the annual cash flow conversion efficiency of Ascelia Pharma AB (publ) from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Ascelia Pharma AB (publ) worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr78.94 Million ≈ $8.50 Million	Skr-62.84 Million ≈ $-6.76 Million	-0.796x	+53.33%
2023-12-31	Skr74.33 Million ≈ $8.00 Million	Skr-126.79 Million ≈ $-13.64 Million	-1.706x	-146.30%
2022-12-31	Skr180.86 Million ≈ $19.46 Million	Skr-125.26 Million ≈ $-13.48 Million	-0.693x	-82.92%
2021-12-31	Skr307.83 Million ≈ $33.13 Million	Skr-116.56 Million ≈ $-12.54 Million	-0.379x	-4.51%
2020-12-31	Skr236.06 Million ≈ $25.40 Million	Skr-85.53 Million ≈ $-9.20 Million	-0.362x	-132.65%
2019-12-31	Skr237.06 Million ≈ $25.51 Million	Skr-36.92 Million ≈ $-3.97 Million	-0.156x	-41.74%
2018-12-31	Skr276.07 Million ≈ $29.71 Million	Skr-30.33 Million ≈ $-3.26 Million	-0.110x	+41.43%
2017-12-31	Skr111.73 Million ≈ $12.02 Million	Skr-20.96 Million ≈ $-2.26 Million	-0.188x	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$7.30 Million

Skr67.87 Million SEK

Market Cap Rank

#27766 Global

#612 in Sweden

Share Price

Skr0.54

Change (1 day)

+0.38%

52-Week Range

Skr0.48 - Skr5.10

All Time High

Skr900.24